ImpriMed to Showcase Groundbreaking AI Research and Applications at Symposium on Artificial Intelligence in Veterinary Medicine (SAVY)
SAVY -- ImpriMed, a leading precision medicine startup focused on leveraging artificial intelligence to improve cancer treatment, today announced its gold-level sponsorship and participation at the upcoming Symposium on Artificial Intelligence in Veterinary Medicine (SAVY) hosted by the Cornell University College of Veterinary Medicine in Ithaca, New York, from April 19-21, 2024. ImpriMed CEO Dr. Sungwon Lim will lead a proffered talk on Saturday, April 20, at 10:30am EDT during the conference's population health and companion animals session.
Lim's oral abstract, presented in collaboration with distinguished veterinary oncologist Dr. Joseph Impellizeri (Cornell D.V.M. ?94), will highlight the revolutionary impact of AI in advancing canine lymphoma treatment. Titled "Improving Canine Lymphoma Treatment Outcomes by Individualizing Drug Selection using Machine-Learning-Based Predictive Models," the presentation will provide functional perspectives on integrating AI and veterinary oncology by examining ImpriMed's pioneering approach to personalized drug response predictions. The company's clinical results, based on thousands of real-world canine lymphoma and leukemia patients, boast three-fold longer survival times and four-fold longer remission in relapsed B-cell canine lymphoma and high-grade T-cell canine lymphoma, improving the efficacy and speed of patient treatment.
ImpriMed's timely insights come amid continued adoption of AI's practical workplace applications in veterinary medicine. Diagnosis and disease detection currently ranks as the third most common use of AI in veterinary medicine, with practitioners reporting significant benefits in diagnosis and treatment (source: Digitail). Emerging AI applications in veterinary medicine are also projected to grow at a compound annual growth rate (CAGR) of around 22 percent from 2023 to 2030, outpacing the broader AI in animal health market growth rate (source: Grand View Research).
This nascent adoption of AI for treatment and diagnostics underscores the need for informed, industry-wide dialogue on harnessing the technology's powerful capability ? a conversation ImpriMed hopes to advance at SAVY.
"As the only company combining AI with a patient's live cancer cell analysis, ImpriMed has developed a uniquely advanced understanding of machine learning's transformative potential. Our research represents a significant step forward in harnessing technological innovation to advance veterinary medicine," said Lim. "By sharing our findings with like-minded peers, we're honored to support SAVY in bridging the gap between academic theory and practical application in veterinary AI."
About ImpriMed
ImpriMed, founded in 2017 in Silicon Valley, is a leading precision medicine startup revolutionizing cancer treatment with artificial intelligence. The company's pioneering drug response prediction technology helps reduce costs, accelerate treatment, enhance efficacy, and improve the quality of life for patients. To date, the company's technology has been deployed across more than 40 U.S. states, and 17,000+ canine and feline blood cancer tests have been performed as of 2024. ImpriMed is redefining the future of oncology treatment with personalized, effective solutions. For additional information, visit www.imprimedicine.com.
News published on and distributed by:
